
New report gives snapshot of state's cultural sector, with many earning less than a living wage
Get Starting Point
A guide through the most important stories of the morning, delivered Monday through Friday.
Enter Email
Sign Up
'The sector is much, much larger than any of us ever imagined,' said MCC executive director Michael Bobbitt. 'It's also struggling financially, both in terms of the size of organizations and the median income of its artists.'
Advertisement
Bobbitt said the report reveals critical weaknesses in the state's arts economy, and he hoped it will serve as a 'call to action' for the state's creative sector, legislators, nonprofits, and businesses.
The weaknesses are 'more severe than we imagined,' he said. 'If we don't change our behavior and our mindset about the cultural sector, the level of crisis is something I'm not sure many will survive.'
All told, the report identifies some 137,000 jobs in the creative sector, about 4 percent of the state's overall workforce. Roughly 25,000 people work at the cultural nonprofits that reported employment data, and the report describes more than 112,000 'generators' — individuals who derive at least half their income from cultural work.
Researchers cautioned, however, that the actual number of people working in the cultural sector is likely much higher. Only a fraction of nonprofits reported employment data, and the inventory does not account for some teachers.
The audit casts a wide net when it comes to creative occupations for these people, including everything from floral designers and technical writers to actors, architects, and editors.
Advertisement
Teresa Nelson, founder and managing principal of Diversity North Group, worked with MCC to compile and analyze the data using a variety of publicly available sources, including IRS 990 forms, libraries, and CreativeGround, an artist database maintained by the New England Foundation for the Arts.
'Mass Cultural chose quite a broad variety, which was exciting and really aligns with how we think about art and culture today,' said Nelson. 'It's not just your traditional dance company and museum, but it's also art as expressed in craft, art as expressed in industrial production, like book binding or other decorative arts.'
The report found the median income across 36 disparate creative occupations was around $49,000, significantly lower than the state's individual living wage of $60,000. Similarly, the individual median incomes for 28 of the listed occupations fell below the state's living wage.
Among the occupations with the lowest median income were musicians, photographers, and performers, with dancers and choreographers having a median income of just more than $7,000. The median income for architects, meanwhile, is more than $88,000.
The research, conducted in 2024, also found persistent income inequality across the sector: Women earn less than men, and white people earn more than people of color. The 'generator' population is also less racially diverse, more highly educated, and has a smaller proportion of immigrants than the state's overall workforce.
Bobbitt said he was most surprised by how 'drastically poor' the sector is.
'This is people literally starving,' he said, invoking the stereotype of the starving artist. 'Any other sector that had those kinds of numbers, it would be a rallying cry.'
Advertisement
Dee Schneidman, NEFA's senior program director for creative economy, said the report's detailed findings are in keeping with previous trends.
'It's pretty consistent with what we've seen over time,' she said. She added that the report will help grant-making agencies 'understand where to focus attention and where the levers of support might be of best use.'
Bobbitt, who in the coming months plans to present the data to legislators, philanthropists, municipal leaders, business associations, and others, said the report's implications go well beyond the state's cultural sector.
If the arts are 'in fact an amenity for the state — something that attracts business, visitors, and residents — then everybody needs to be a part of the solution,' he said, adding that he hoped the report would inform new policy to incorporate the arts into workforce-development programs. 'We're not going to be able to solve this with grants alone.'
Malcolm Gay can be reached at
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Upturn
07-08-2025
- Business Upturn
Sigachi Industries begins civil works for 12,000 MTPA MCC expansion at Dahej SEZ
Sigachi Industries Limited, a leading name in pharmaceutical excipients and specialty ingredients, has begun civil works for a major capacity expansion at its Dahej SEZ unit in Gujarat. The company has recently informed exchanges that it is establishing a new 12,000 MTPA Microcrystalline Cellulose (MCC) facility as part of its ongoing commitment to scale operations, with a focus on safety, quality, and global leadership. This move marks an important step forward in strengthening operational resilience, especially as Sigachi continues to recover from the recent incident at its Pashamylaram unit, which remains under investigation. Despite the setback, the company is pushing ahead with a strong vision. The upcoming facility at Dahej is being developed with advanced safety systems and equipment sourced in collaboration with top-tier manufacturers and safety consultants. Once completed in the next nine months, the project will boost Sigachi's total MCC capacity to 30,000 MTPA, making it the largest manufacturer of MCC in India and one of the top players globally. With ongoing enhancements at its Jhagadia and existing Dahej units, Sigachi is ensuring consistent supply to its global customers, underscoring its focus on business continuity and industry excellence. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at


Business Wire
26-06-2025
- Business Wire
IPinfo Launches IPinfo Plus: High-Resolution IP Privacy Data for Greater Certainty
SEATTLE--(BUSINESS WIRE)--IPinfo, the internet data company, today announced the launch of IPinfo Plus, a new product that delivers high-resolution IP intelligence designed to support advanced risk modeling, threat detection, and compliance efforts. Built for organizations that need more than boolean flags and basic location data, IPinfo Plus offers granular context across geolocation, privacy detection, network infrastructure, mobile carrier data, and ASN data. 'With IPinfo Plus, we're giving security and compliance teams the precision they need to act with certainty,' said Ben Dowling, CEO of IPinfo. 'Our goal is to eliminate guesswork from IP intelligence by providing detailed, verified data at scale. Instead of just knowing if an IP is using anonymizing technology, they'll know what kind of service it's using. Rather than simply knowing an IP's city, they'll see the accuracy radius and the last time the IP geolocation and ASN data changed.' With 32 enriched IP attributes, IPinfo Plus converts raw IPs into clear signals so fraud, security, and compliance teams can act without second-guessing: Location Precision: Know the exact geographic precision with accuracy radius in kilometers around the coordinates, helping you determine if the location data meets your requirements for geo-based rules and compliance. Privacy Clarity: Identify the exact anonymity layer and provider (VPN, proxy, Tor, relay) instead of a vague flag, enabling tailored controls. Carrier Details: Surface carrier name and MCC/MNC codes so you can build carrier-specific rules, detect SIM-swap risk, or offer direct-bill payment only on supported networks. Network Change Detection: See last-changed timestamps for both geolocation and ASN data to help identify recently reassigned IP ranges and infrastructure shifts: critical for detecting potential fraud or security risks from freshly allocated IPs. Infrastructure Identification: Get hosting, anycast, and satellite indicators that classify network types, while hostname resolution provides reverse DNS for deeper infrastructure profiling and verification. IPinfo Plus Use Cases Include: VPN and proxy service identification: Identify specific anonymizing services and providers to build targeted security policies and access controls IP reassignment detection: Monitor geo and ASN change timestamps to flag recently reassigned IP ranges that may pose higher fraud risk Mobile carrier fraud prevention: Implement carrier-specific rules using MCC/MNC codes and carrier names to detect SIM-swap attacks or enable direct billing on verified networks Location-based compliance: Use accuracy radius to determine if geolocation precision meets regulatory requirements for content licensing, tax calculation, or data residency Learn More IPinfo Plus is available starting at $62/month (with annual commitment) for 150,000 API requests, with flexible pricing tiers up to 1M requests on monthly or annual plans. Data is available via API, database download, Snowflake Marketplace, or Google Cloud Marketplace (US and EU). Developers can sign up today to get started with the API at Full documentation is available to get started in minutes. IPinfo is the internet data company, providing the world's most accurate IP data that delivers highly contextual metadata on each IP address, from geolocation and mobile carrier to privacy detection and proxies. IPinfo is trusted by more than 500,000 users, from developers to Fortune 500 companies, who use IP data to make smarter decisions, mitigate security risks, ensure regulatory compliance, and drive better customer experiences. IPinfo's robust and secure API processes more than 1 billion requests daily, with data also available through direct download and leading cloud platforms, all backed by a team of data experts who are committed to precision. Discover the power of better IP data at
Yahoo
09-06-2025
- Yahoo
FDA Removes Partial Clinical Hold on TuHURA Biosciences' Phase 3 Accelerated Approval Trial for IFx-2.0 in Advanced or Metastatic Merkel Cell Carcinoma
Company anticipates initiating its Phase 3 accelerated approval trial of IFx-Hu2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as first-line treatment for advanced and metastatic Merkel cell carcinoma (MCC), conducted under Special Protocol Assessment (SPA) Agreement with U.S. Food and Drug Administration (FDA), later in June 2025 Resolution of partial clinical hold unlocks second tranche of funds from $12.5 million PIPE financing announced on June 3, 2025 TAMPA, Fla., June 9, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that the FDA has removed the manufacturing-related partial clinical hold on the Company's Phase 3 accelerated approval trial for IFx-2.0, thereby allowing the trial to proceed as agreed to under the previously announced SPA Agreement with the FDA. "We are grateful for the collaborative interaction with the reviewers at the Office of Therapeutic Products (OTP) and the Oncology Center of Excellence (OCE), including their quick response time and, importantly, their helpful recommendations going forward," stated James Bianco, M.D., President and Chief Executive Officer of TuHURA Biosciences. "The removal of the partial clinical hold allows TuHURA to begin the trial's initiation and activation of clinical sites for the Phase 3 accelerated approval trial of IFx-2.0," continued Dr. Bianco. "We are also pleased that the removal of the partial clinical hold represents the achievement of the second milestone funding condition under our recently announced private placement, thereunder trigging the payment to the Company of an additional $2.23 million under the financing." The Company's Phase 3 accelerated approval trial of IFx-2.0, will be conducted under an SPA Agreement with the U.S. FDA, and will evaluate IFx-2.0 as an adjunctive therapy administered weekly for three weeks concurrent with the approved dose and schedule for Keytruda® compared to Keytruda® plus placebo in the first line treatment of patients with advanced or metastatic MCC. Keytruda® is currently approved in MCC under accelerated approval based on Overall Response Rate (ORR). The pivotal trial for IFx-2.0 is expected to enroll 118 across approximately 22 to 25 U.S. sites. Trial participants will be randomized on a 1:1 basis and receive Keytruda® in both arms, for up to two years, or until disease progression or Keytruda® related toxicities. The primary endpoint for the trial is ORR with a key secondary endpoint of Progression Free Survival (PFS). Other secondary endpoints are safety, duration of response, and overall survival. Accelerated approval is based on the successful achievement of the ORR primary endpoint. PFS, the key secondary endpoint, if successfully achieved, without a detrimental effect on overall survival, could satisfy the requirement for regular approval without the requirement for a post approval confirmatory trial (in contrast to most accelerated approval trials). About TuHURA Biosciences, Inc. TuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 immuno-oncology company developing novel technologies to overcome primary and acquired resistance to cancer immunotherapy, two of the most common reasons cancer immunotherapies fail to work or stop working in the majority of patients with cancer. TuHURA's lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) compared to Keytruda® plus placebo in first-line treatment for advanced or metastatic Merkel Cell Carcinoma. Following its proposed merger with Kineta, Inc., if completed, the Company expects to advance Kineta's novel VISTA inhibiting antibody into a randomized Phase 2 trial in NPM1 mutated r/r AML in combination with a menin inhibitor. In addition to its innate immune agonist product candidate, TuHURA is leveraging its Delta Opioid Receptor technology to develop first-in-class, bi-specific antibody drug conjugates and antibody peptide conjugates targeting Myeloid Derived Suppressor Cells to inhibit their immune-suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies. For more information, please visit and connect with TuHURA on Facebook, X, and LinkedIn. CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This press release contains certain "forward-looking statements" within the meaning of, and subject to the safe harbor created by, Section 27A of the Securities Act, Section 21E of the Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and other future conditions. In some cases you can identify these statements by forward-looking words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "could," "should," "would," "project," "plan," "expect," "goal," "seek," "future," "likely" or the negative or plural of these words or similar expressions. Examples of such forward-looking statements include but are not limited to express or implied statements regarding TuHURA's expectations, hopes, beliefs, intentions or strategies regarding the future and include, without limitation, statements regarding, TuHURA's IFx-Hu2.0 product candidate and anticipated Phase 3 trial, its tumor microenvironment modulators development program, its potential acquisition by merger of Kineta Inc. and the statements about Kineta's VISTA-101 development program, and any developments or results in connection with the foregoing and the anticipated regulatory pathway and timing of the foregoing development programs, studies and trials. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. You are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in these forward-looking statements. Factors that could cause actual results to differ materially from these forward-looking statements are described in detail in our registration statements, reports and other filings with the SEC, which are available on the combined company's website, and at The forward-looking statements and other information contained in this press release are made as of the date hereof, and TuHURA does not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. Nothing herein shall constitute an offer to sell or the solicitation of an offer to buy any securities. Investor Contact: Monique KosseGilmartin GroupMonique@ View original content to download multimedia: SOURCE TuHURA Biosciences, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data